# Fluent

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/fluent-3

- Industry: Medical Devices & Equipment
- Headquarters: Sydney, Australia
- Website: www.fluentbci.com/
- Total disclosed funding: $1.4M
- Latest round: Seed (Jun 30, 2026)
- Investors on record: 6

## About

Fluent BCI Holdings Pty Ltd, based in Sydney, Australia, specializes in innovative neural interface technology aimed at enhancing communication for individuals with disabilities, transforming thought into text seamlessly. Founded by co-founders Tim Mahoney (CEO) and Dean Freestone (CTO), in 2025, Fluent BCI Holdings Pty Ltd is focused on developing technology that translates intended speech directly from thought. The company operates out of Sydney, Australia, and has secured its initial funding through a Seed round. The founder's history is not widely documented. In June 2026, Fluent BCI Holdings Pty Ltd raised AUD 2 million in seed funding from Tanarra Capital, Galileo Ventures, MSWA, Jumpspace Ventures, Founders Factory, and Pacific Channel. Individual and other investors also participated in the round. Fluent's core product is the InScribe neural interface, which translates thoughts into text, helping individuals with conditions like anarthria and dysarthria communicate effectively. The technology utilizes safe, subscalp neural connections and is currently under development in Melbourne, Australia, with future clinical studies aimed at the U.S. market for assistive communication solutions.Fluent's revenue structure is primarily based on partnerships and clinical research collaborations, as the company has not yet commercialized its products. Revenue is expected to be generated through direct engagements with healthcare institutions and potential licensing agreements post-regulatory approvals. Future pricing strategies may include subscription fees for ongoing support and one-time fees for the deployment of the technology in clinical settings.  Fluent raised AUD 2 million in Seed funding to develop its sub-scalp brain-computer interface, expand engineering efforts, complete regulatory submissions, and commence first-in-human clinical trials in Melbourne. The company aims to launch its InScribe technology in targeted markets, focusing on healthcare providers that require assistive solutions. This funding will facilitate the growth of engineering capabilities and accelerate the timeline for clinical trials, ultimately driving the introduction of their technology into clinical environments.

## Funding rounds

- Seed, Jun 30, 2026, $1.4M — Tanarra Capital, Pacific Channel, Galileo Ventures, Founders Factory, Jumpspace Ventures, Multiple Sclerosis Western Australia

## Investors

- Tanarra Capital (https://capitalatlas.ai/funds/tanarra-capital) — Seed
- Pacific Channel (https://capitalatlas.ai/funds/pacific-channel) — Seed
- Galileo Ventures — Seed
- Founders Factory (https://capitalatlas.ai/funds/founders-factory) — Seed
- Jumpspace Ventures (https://capitalatlas.ai/funds/jumpspace-ventures) — Seed
- Multiple Sclerosis Western Australia — Seed